BioCryst Pharmaceuticals
BCRX
BCRX
115 hedge funds and large institutions have $384M invested in BioCryst Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 45 increasing their positions, 27 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
115
Holders Change
-2
Holders Change %
-1.71%
% of All Funds
2.87%
Holding in Top 10
4
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-50%
% of All Funds
0.1%
New
16
Increased
45
Reduced
27
Closed
16
Calls
$6.27M
Puts
$2.01M
Net Calls
+$4.26M
Net Calls Change
-$7.88M
Top Buyers
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
$28.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
$17.4M |
| 3 |
State Street
Boston,
Massachusetts
|
$21.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
$33.4M |
| 5 |
Millennium Management
New York
|
$18.9M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
CSS
126
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$118K | -14,016 | Closed |
|
|
QSS
127
Quantitative Systematic Strategies
Ponte Vedra Beach,
Florida
| – | -$115K | -13,631 | Closed |
|
|
TSS
128
Two Sigma Securities
New York
| – | -$87K | -10,396 | Closed |
|
129
Nisa Investment Advisors
St. Louis,
Missouri
| – | -$8K | -1,000 | Closed |
|
|
PCM
130
Prelude Capital Management
New York
| – | -$7K | -800 | Closed |
|
|
MIM
131
Monashee Investment Management
Boston,
Massachusetts
| – | -$1.68M | – | – |
|